Imagen de Portada

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Daniel Q. Huang, Yen Thi‐Hai Pham, Hung N. Luu
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

PNPLA3 Genotype and Clinical Factors Impact Hepatocellular Carcinoma Risk: Findings From a Prospective Cohort Study
por: Daniel Q. Huang, et al.
Publicado: (2026)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
por: Jonggi Choi
Publicado: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
por: Yu‐Sheng Lin, et al.
Publicado: (2026)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
por: Shuaibing Ying, et al.
Publicado: (2026)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
por: Yu‐Sheng Lin, et al.
Publicado: (2026)

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. Authors' Reply
por: Elisa Pinto, et al.
Publicado: (2026)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
por: Gamal Shiha, et al.
Publicado: (2025)

Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply
por: Subin Heo, et al.
Publicado: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma—Authors' Reply
por: Jiwon Yang, et al.
Publicado: (2025)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
por: Lesley A. Patmore, et al.
Publicado: (2025)

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors?
por: Yuanyan Sun, et al.
Publicado: (2026)

Editorial: Understanding the Role of the Alpha‐1 Pi* MZ Genotype in the Development of Hepatocellular Carcinoma for Patients With ACLD
por: Kaitlyn Carlson, et al.
Publicado: (2026)

Editorial: Direct‐Acting Agents and Risk of Hepatocellular Carcinoma—The End of Controversy
por: Vincent Haghnejad, et al.
Publicado: (2025)

Editorial: Flipping the Script—Higher Risk of Hepatocellular Carcinoma With Tenofovir Compared to Entecavir in a French Population‐Based Cohort
por: Ariel Lee, et al.
Publicado: (2025)

Letter: Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply
por: Kuo‐Cheng Wu, et al.
Publicado: (2024)

Editorial: TIPS in the Era of Aging and Metabolic Comorbidity—Rethinking Risks and Rewards. Authors Reply
por: Michelle Spaan, et al.
Publicado: (2026)

Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice—Authors' Reply
por: Nikolaj Torp, et al.
Publicado: (2025)

Letter: Enhancing HCC Surveillance: GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety—Authors' Reply
por: Gamal Shiha, et al.
Publicado: (2025)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Authors' reply
por: L. Aceituno, et al.
Publicado: (2026)

Editorial: Do we Need to Adapt GERD Metrics Based on the Population Being Evaluated? Authors' Reply
por: Walter W. Chan, et al.
Publicado: (2026)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
por: Pei‐Chien Tsai, et al.
Publicado: (2026)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
por: Ramin Ebrahimi, et al.
Publicado: (2025)

Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
por: Jiong Yu, et al.
Publicado: (2024)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
por: Yu‐Sheng Lin, et al.
Publicado: (2026)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
por: Jianhui Zhao, et al.
Publicado: (2024)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
por: Jeongkuk Seo, et al.
Publicado: (2024)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
por: Máté Szilcz, et al.
Publicado: (2025)

Editorial: ‘Risk‐Adapted Starting Ages of Colorectal Cancer Screening for People With Diabetes or Metabolic Syndrome’. Authors' Reply
por: Hermann Brenner, et al.
Publicado: (2025)

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
por: Kanghee Park, et al.
Publicado: (2025)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
por: Jian Wang, et al.
Publicado: (2025)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
por: David Mehdi Asgher Niazi, et al.
Publicado: (2026)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
por: Raj Vuppalanchi, et al.
Publicado: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
por: Fai Fai Ho, et al.
Publicado: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
por: Suprabhat Giri, et al.
Publicado: (2025)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply
por: Ryan M. Mathias, et al.
Publicado: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
por: Federica Tavaglione, et al.
Publicado: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
por: Parul Tandon, et al.
Publicado: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
por: Bharati Kochar, et al.
Publicado: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
por: Jeffrey D McCurdy, et al.
Publicado: (2025)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
por: Jessica D. Lee, et al.
Publicado: (2025)